source
- Novartis' $12B Avidity deal falters as DM1 therapy misses Phase 3 endpointNovartis' recent acquisition of Avidity Biosciences was intended to bring a novel therapy for Myotonic dystrophy type 1 (DM1) into its portfolio. The drug, del-desiran, an antibody-oligonucleotide…
- Biotech sector expected to weather Fed rate hike despite higher capital costsThe Federal Reserve raised the federal funds rate by a quarter of a percentage point, a move that traditionally weighs on capital‑intensive industries like biotech. Analysts at BMO Capital Markets…